Page last updated: 2024-08-21

pyrazines and angiogenin

pyrazines has been researched along with angiogenin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Angeles, T; Clapper, ML; Robinson, C; Ruggeri, BA; Wilkinson, J	1
Apperley, JF; Crawley, D; Lampert, I; Naresh, K; Politou, M; Rahemtulla, A; Terpos, E	1

Other Studies

2 other study(ies) available for pyrazines and angiogenin

Article	Year
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Cell Division; Dose-Response Relationship, Drug; Endothelium, Vascular; Hemangiosarcoma; Humans; Insulin-Like Growth Factor I; Liver; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic; Thiones; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta haematologica, 2005, Volume: 114, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A	2005

Article

Year

The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:1

Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Cell Division; Dose-Response Relationship, Drug; Endothelium, Vascular; Hemangiosarcoma; Humans; Insulin-Like Growth Factor I; Liver; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic; Thiones; Thiophenes; Transplantation, Heterologous; Tumor Cells, Cultured

2002

Anti-angiogenic effect of bortezomib in patients with multiple myeloma.

Acta haematologica, 2005, Volume: 114, Issue:3

Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A

2005